Pharmaceuticals · SLPA
Pharma - API & CRAMS
from 722 today
Revenue grew 45% YoY to Rs.4,658mn, coming in 6% below our estimate but marginally ahead of consensus estimates by 1%. We revise our target valuation multiple and retain hold on the stock with a revised PT of Rs. 635.
Shilpa Medicare delivered a strong 1QFY27 driven by API, Formulations, and Biologics growth, and the company is well positioned for a sustained earnings acceleration supported by complex formulations and a robust pipeline.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
